Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    KEFI Gold and Copper

    MCap

    GBP38m

    Last close

    GBP0.01

    ▲ 0.11 (20.00%)

    Vection Technologies

    MCap

    AUD24m

    Last close

    AUD0.02

    ▲ 0.00 (16.67%)

    OpGen

    MCap

    USD7m

    Last close

    USD0.49

    ▲ 0.05 (11.62%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Oryzon Genomics (BME: ORY)

Last close As at 19/07/2024

EUR1.91

▲ −0.01 (−0.31%)

Market capitalisation

EUR123m

Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. Central nervous system (CNS) asset vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder, and is in a Phase IIb trial for schizophrenia.

Oryzon is among the leading clinical-stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and a potentially favourable safety/efficacy profile compared with the first-generation HDAC inhibitors.

Latest Insights

View More

Healthcare | Flash note

Oryzon Genomics — Strengthening vafidemstat’s IP profile

Healthcare | Flash note

Oryzon Genomics — Encouraging interim update on FRIDA

Healthcare | Flash note

Oryzon Genomics — ALICE data published in The Lancet Haematology

Healthcare | Flash note

Oryzon Genomics — EC taps Oryzon for healthcare initiative
testalize-me-0jE8ynV4mis-unsplash
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Carlos Buesa

    CEO

Balance Sheet

Forecast net cash (€m)

19.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 1.1 0.8 (7.7)
Relative 0.8 (2.4) (21.3)
52 week high/low €2.2/€1.6

Financials

Oryzon Genomics continues to fortify its IP profile for vafidemstat, which is being developed for borderline personality disorder (BPD) and for the potential application to attention deficit hyperactivity disorder (ADHD). Oryzon has received positive acceptance decisions for two incremental patent applications from the Japanese Patent Office (JPO), which should provide protection until 2040 (excluding potential extensions). Oryzon was also notified of similar patent grants from the European and Korean patent offices, which may extend the drug’s exclusivity in those jurisdictions. Oryzon is advancing its lead CNS asset towards an end-of-Phase II (EoP2) meeting with the FDA to discuss a potentially registrational Phase III trial in BPD. Vafidemstat already holds composition of matter patents in the US and EU providing protection up to 2037 and 2036, respectively.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2022A 15.7 (5.3) (6.3) (7.49) N/A N/A
2023A 14.2 (4.4) (6.0) (5.65) N/A N/A
2024E 12.9 (3.1) (4.1) (2.53) N/A N/A
2025E 33.7 16.9 15.4 29.08 6.6 6.5

Research

Flash note

Healthcare

Oryzon Genomics — Encouraging interim update on FRIDA
testalize-me-0jE8ynV4mis-unsplash

Flash note

Healthcare

Oryzon Genomics — ALICE data published in The Lancet Haematology

Healthcare

Flash note

Oryzon Genomics — Strengthening vafidemstat’s IP profile
View All

Further insights

insight

Epigenetics

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free